Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
Key Highlights
- ➤Cash $348.9M supports operational runway into first half of 2028
- ➤SGT-003 generally well tolerated across 53 INSPIRE DUCHENNE participants
- ➤FDA Type C meeting planned late Q4 2026 on potential accelerated approval
- ➤SGT-212 dosed five FALCON participants; initial data expected Q1 2027
- ➤Q3 net loss $53.9M versus $45.8M a year earlier
Expert Statements
Bo Cumbo, President and CEO of Solid Biosciences
“As we approach key regulatory and clinical catalysts in our Duchenne and Friedreich’s ataxia programs, our progress this quarter reflects the dedication of our team, the differentiated nature of our clinical programs and the strength of our delivery technologies.”
Bo Cumbo, President and CEO of Solid Biosciences
“In Duchenne, we look forward to meeting with the FDA late in the fourth quarter of 2026 to discuss a potential accelerated approval pathway for SGT-003. Our clearly differentiated safety data are central to those discussions.”
Bo Cumbo, President and CEO of Solid Biosciences
“Across 53 participants dosed in INSPIRE DUCHENNE, SGT-003 has demonstrated an encouraging safety profile using a low-burden, steroid-only immunomodulation regimen.”
Bo Cumbo, President and CEO of Solid Biosciences
“The Duchenne community deserves continued progress on both efficacy and safety, and that is what we are working to deliver.”
Bo Cumbo, President and CEO of Solid Biosciences
“In Friedreich's ataxia, we have dosed five participants in the FALCON trial, and SGT-212 recently received Orphan designation from the European Commission.”
Bo Cumbo, President and CEO of Solid Biosciences
“While cardiac disease remains the leading cause of mortality in FA, the FA patient community has consistently told us that slowing the relentless neurologic decline is their top priority.”
Bo Cumbo, President and CEO of Solid Biosciences
“SGT-212 is designed to address both manifestations of the disease, and we believe its dual-route administration is what may uniquely enable SGT-212 to address the full scope of the disease.”
Bo Cumbo, President and CEO of Solid Biosciences
“We anticipate reporting initial data in the first quarter of 2027”
- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 -
- Solid has scheduled a Type C meeting with the FDA in late Q4 2026 to discuss the preliminary INSPIRE DUCHENNE SGT-003 data package and to seek guidance on a potential accelerated approval pathway for SGT-003 -
Get started
Create a free account to read the full story.